Medtech leader with deep orthopedic extremities experience enhances board depth as shoulder-focused company advances growth and strategic objectives
Catalyst OrthoScience Appoints Gordon Van Ummersen to Board of Directors

NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the appointment of Gordon Van Ummersen to its board of directors.
“Catalyst is an exciting shoulder-focused company that has built a compelling platform with meaningful differentiation and surgeon partnership. I look forward to playing an active role in advancing execution across the company’s next phase of growth.”Share
“I am pleased to join Catalyst OrthoScience’s board at this important stage of the company’s evolution,” said Van Ummersen. “Catalyst is an exciting shoulder-focused company that has built a compelling platform focused on meaningful differentiation and surgeon partnership, and I look forward to playing an active role in advancing execution across the company’s next phase of growth.”
Van Ummersen has held executive leadership positions across Fortune 100 healthcare and medical technology companies, with a proven track record in driving commercial scale, advancing innovation pipelines, and guiding organizations through pivotal phases of growth and transformation.
“Gordon’s perspective and experience will be invaluable as we execute the next phase of our growth strategy and continue to deepen our relationships within the shoulder community,” said Carl O’Connell, president and chief executive officer of Catalyst. “His leadership aligns perfectly with our commitment to differentiated, surgeon-driven solutions that improve procedural efficiency and outcomes.”
Van Ummersen’s appointment is effective immediately.
About Catalyst OrthoScience Inc.
Catalyst OrthoScience, founded in 2014 by orthopedic surgeon Dr. Steven Goldberg and based in Naples, Fla., is redefining shoulder replacement surgery. With a focus on less invasive techniques, fewer complications, and a more natural-feeling shoulder, Catalyst is breaking away from traditional approaches. Our total shoulder systems are engineered for precision and efficiency – preserving bone and soft tissue while enabling delivery of consistent, reproducible results. With a growing portfolio of issued and pending patents, Catalyst technology is available across the U.S. Learn more at www.catalystortho.com and connect with us on LinkedIn and Instagram.
Contacts
Nicole Nelson
Media Relations
(239) 325-9976
Author
The De Angelis Group | Orthopedics This Week | MSK Innovations

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.